by Madaline Spencer | Dec 12, 2025
The U.S. Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel) for the treatment of patients ages 6 months and older with Wiskott-Aldrich syndrome (WAS). WAS is a disease with immunological deficiency and reduced ability to form blood...
by Madaline Spencer | Dec 12, 2025
Maja Kostic, MD, PhD, neuro-ophthalmologist at Bascom Palmer Eye Institute and Assistant Professor of Ophthalmology at the University of North Carolina at Chapel Hill, discusses advancing thyroid eye disease (TED) care. TED is a rare autoimmune disease...
by Madaline Spencer | Dec 11, 2025
The U.S Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed/refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy. MZL is a usually...
by Madaline Spencer | Dec 11, 2025
Carla Nester, MD, Professor of Pediatrics-Nephrology at the University of Iowa, discusses one-year phase 3 data of Empaveli (pegcetacoplan) for treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and...
by Madaline Spencer | Dec 10, 2025
Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, discusses interim results from a study testing mezagitamab for the treatment of immunoglobulin A (IgA) nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA...
